Novotech

Novotech is a clinical research organization (CRO) founded in 1997 in Australia and headquartered in Singapore. It provides a range of clinical trial services including medical and regulatory consulting, site selection, early phase trials, clinical operations, and biometrics. The company has expanded globally through acquisitions and investments, and has been recognized as a leading biotech CRO.

Novotech was founded in 1997 in Australia and is headquartered in Singapore. In 2026, Novotech moved its headquarters to Singapore and appointed Dr. Anand Tharmaratnam as CEO. In 2025, Novotech welcomed new investment from GIC, Temasek, and existing investor TPG. In 2023, Novotech expanded to Europe with the acquisition of Clinical CRO EastHORN. In 2022, Novotech expanded to the US with acquisitions of NCGS and CBR International. In 2021, Novotech acquired shareholdings in ObvioHealth and Prospection. In 2020, Novotech Group and PPC Group merged to form Novotech Health Holdings. In 2019, PPC Group acquired Biosuntek. In 2018, Novotech acquired CNS and PPC launched Acrostar SMO. In 2017, TPG acquired a controlling stake in Novotech and PPC. In 2007, Novotech Group began its entry into Asian markets. In 1997, Novotech Group was founded with an initial focus on regulatory affairs, and PPC Group was founded.

1. Biotech's Partner at Every Phase – Novotech CRO
2. Our Story | Novotech CRO
3. Press Releases | Novotech CRO